This is a randomized, double blinded, controlled phase I clinical study. To evaluate the safety and immunogenicity of receiving two doses of MVA strain monkeypox attenuated live vaccine in individuals aged 18 years and above.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Immediate adverse events
Timeframe: 60 minutes after each dose of vaccination
Solicited Adverse Events
Timeframe: 14 days after each dose of vaccination
Unsolicited Adverse Events
Timeframe: 28 or 30 days after each dose of vaccination
Abnormal incidence rate of electrocardiogram
Timeframe: 14 days after each dose of vaccination
Serious Adverse Events (SAE)
Timeframe: 12 months after the last dose
Adverse Event of Special Interest (AESI)
Timeframe: 12 months after the last dose